FibroGen, Inc. (FGEN) Stock Analysis

FibroGen, Inc. (FGEN) Healthcare & Pipeline Overview

FibroGen, Inc. is a biopharmaceutical company specializing in therapeutics for anemia and fibrosis-related diseases. Their lead product, Roxadustat, addresses anemia in chronic kidney disease, while Pamrevlumab targets idiopathic pulmonary fibrosis and other fibrotic conditions. The company operates through strategic collaborations with Astellas and AstraZeneca.

What Is the Investment Thesis for FGEN?

FibroGen's investment thesis hinges on the successful commercialization of Roxadustat and the clinical advancement of Pamrevlumab. Roxadustat's potential in the anemia market, particularly for chronic kidney disease patients, represents a significant revenue opportunity. The company's strategic partnerships with Astellas and AstraZeneca provide financial support and market access. Pamrevlumab's Phase III trials across multiple fibrotic indications, including IPF and pancreatic cancer, offer substantial upside potential if clinical endpoints are met. However, regulatory hurdles, clinical trial outcomes, and competition in the biotechnology sector pose risks. The company's current market capitalization of $36.7M reflects both the potential and the risks associated with its pipeline.

Based on FMP financials and quantitative analysis

FGEN Key Highlights

Market capitalization of $36.7M indicates the company's current valuation in the market.

• P/E ratio of 0.20 suggests the company is generating earnings relative to its stock price.
• Profit margin of 2848.2% highlights strong profitability, potentially from licensing or collaboration revenues.
• Gross margin of 75.8% reflects efficient cost management in product development and manufacturing.
• Beta of 0.77 indicates lower volatility compared to the overall market, suggesting a more stable investment.

Who Are FGEN's Competitors?

FGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FGEN's Key Strengths?

Proprietary drug candidates targeting unmet medical needs.

• Positive clinical trial data for Roxadustat and Pamrevlumab.
• Strategic collaborations with Astellas and AstraZeneca.
• Experienced management team with expertise in drug development.

What Are FGEN's Weaknesses?

Reliance on a limited number of key products.

• High R&D expenses and long development timelines.
• Dependence on regulatory approvals for commercialization.
• Relatively small market capitalization compared to competitors.

What Could Drive FGEN Stock Higher?

FGEN catalyst: Potential regulatory approvals for Pamrevlumab in IPF, pancreatic cancer, liver fibrosis, diabetic kidney disease, and Duchenne muscular dystrophy.

• Continued commercialization and market penetration of Roxadustat in approved regions.
• Data readouts from ongoing clinical trials for Pamrevlumab.
• Announcement of new strategic collaborations or partnerships.

What Are the Key Risks for FGEN?

Financial-distress signal — its Altman Z-Score of -23.94 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Failure to obtain regulatory approvals for Roxadustat or Pamrevlumab in key markets.
• Unfavorable clinical trial results for Pamrevlumab.
• Competition from established pharmaceutical companies and generic drugs.
• Dependence on strategic collaborations for revenue and market access.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for FGEN?

• Expansion of Roxadustat into new markets: Roxadustat has already been approved in several regions, including China and Japan. Further expansion into additional markets, such as emerging economies with growing CKD populations, represents a significant growth opportunity. This expansion could increase revenue streams and solidify FibroGen's global presence in the anemia treatment market. Timeline: Ongoing.
• Advancement of Pamrevlumab through clinical trials: Pamrevlumab is currently in Phase III clinical development for multiple indications, including IPF, pancreatic cancer, liver fibrosis, diabetic kidney disease and Duchenne muscular dystrophy. Positive clinical trial results and subsequent regulatory approvals could significantly expand the drug's market potential and drive revenue growth. Timeline: 2027-2028.
• Strategic collaborations and partnerships: FibroGen's existing collaborations with Astellas and AstraZeneca provide financial support and market access. Pursuing additional strategic partnerships with other pharmaceutical companies or research institutions could further accelerate the development and commercialization of its pipeline products. These collaborations can also provide access to new technologies and expertise. Timeline: Ongoing.
• Development of new therapeutic candidates: FibroGen can leverage its expertise in fibrosis and anemia to develop new therapeutic candidates targeting other unmet medical needs. This could involve exploring new drug targets, developing novel drug delivery systems, or expanding into new therapeutic areas. A diversified pipeline reduces the company's reliance on its lead products and enhances its long-term growth prospects. Timeline: 3-5 years.
• Exploration of combination therapies: Combining Roxadustat or Pamrevlumab with other existing therapies could enhance their efficacy and expand their therapeutic applications. For example, combining Pamrevlumab with other anti-fibrotic agents could provide a more comprehensive treatment approach for IPF. Exploring these combination therapies could create new market opportunities and improve patient outcomes. Timeline: 2-3 years.

What Are FGEN's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Established clinical data supporting the efficacy of Roxadustat and Pamrevlumab.
• Strategic partnerships with major pharmaceutical companies.
• Expertise in developing therapeutics for anemia and fibrotic diseases.

What Does FGEN Do?

FibroGen, Inc., founded in 1993 and headquartered in San Francisco, California, is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics for serious unmet medical needs. The company's primary focus is on addressing anemia and fibrotic diseases. Its lead product candidate, Roxadustat, is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases (HIF-PH). Roxadustat has completed Phase III clinical development for treating anemia in chronic kidney disease (CKD) across the United States, Europe, China, and Japan. Additionally, it is in Phase II/III development in China for anemia associated with myelodysplastic syndromes (MDS). FibroGen is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF). Pamrevlumab is currently in Phase III clinical development for treating idiopathic pulmonary fibrosis (IPF), pancreatic cancer, liver fibrosis, diabetic kidney disease, and Duchenne muscular dystrophy (DMD). The company operates through strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB to develop and commercialize its products in various global markets. FibroGen's research and development efforts are aimed at providing innovative treatments for patients with limited therapeutic options.

What Products and Services Does FGEN Offer?

• Discovers and develops therapeutics for unmet medical needs.
• Focuses on treatments for anemia and fibrotic diseases.
• Develops Roxadustat, an oral treatment for anemia in chronic kidney disease.
• Develops Pamrevlumab, a monoclonal antibody for fibrotic diseases like IPF.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approvals for its products in various global markets.
• Collaborates with pharmaceutical companies like Astellas and AstraZeneca.

How Does FGEN Make Money?

• Develops and patents novel therapeutic candidates.
• Conducts clinical trials to demonstrate efficacy and safety.
• Out-licenses or co-develops products with larger pharmaceutical companies.
• Generates revenue through milestone payments, royalties, and product sales.

What Industry Does FGEN Operate In?

FibroGen operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for anemia treatments, particularly in chronic kidney disease, is substantial and growing, driven by an aging population and increasing prevalence of CKD. The fibrosis market, including IPF and liver fibrosis, also represents a significant unmet medical need with limited treatment options. FibroGen competes with established pharmaceutical companies and other biotechnology firms developing novel therapies in these areas. Success in this industry requires strong scientific expertise, successful clinical trials, and effective commercialization strategies.

Who Are FGEN's Key Customers?

• Patients with anemia associated with chronic kidney disease.
• Patients with idiopathic pulmonary fibrosis (IPF).
• Patients with pancreatic cancer, liver fibrosis, and diabetic kidney disease.
• Pharmaceutical companies like Astellas and AstraZeneca through collaboration agreements.

Company Profile

FibroGen, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Thane Wettig. FGEN has traded publicly since 2014.

FibroGen, Inc. Financial Trajectory

FibroGen, Inc. (FGEN) reported $-1.5M in revenue for Jun 2026, a decline of 139.4% compared to the prior quarter. The company recorded net income of $12.0M, with diluted EPS of $2.96. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, FGEN averaged $11.32 in diluted EPS.

How FibroGen, Inc. Is Valued

FibroGen, Inc. carries a market capitalization of $36.7M, placing it in the micro-cap category.

FGEN trades at a trailing price-to-earnings ratio of 0.20, below the Healthcare sector average of ~21.50x. A current ratio of 2.69 indicates the company holds enough short-term assets to cover its near-term obligations.

FibroGen, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -23.94 places it in the distress zone, a signal of elevated financial risk.

FibroGen, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 428.1% below estimates on average.

Wall Street analysts project FibroGen, Inc. revenue of about $6.1M for fiscal 2026, with EPS near $-11.95.

FGEN Financials

FGEN Latest News

Common Questions About FGEN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources